IL-6 Activated JAK/STAT3 Pathway and Sensitivity to Hsp90 Inhibitors in Multiple Myeloma

E-ISSN： 1875-533x|21|26|3042-3047

ISSN： 0929-8673

Source： Current Medicinal Chemistry, Vol.21, Iss.26, 2014-09, pp. : 3042-3047

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Targeting the JAK-STAT pathway in lymphoma: a focus on pacritinib

By Derenzini Enrico

Expert Opinion on Investigational Drugs, Vol. 22, Iss. 6, 2013-09 ,pp. : 775-785

Informa Healthcare

Access to resources Recommend Favorite

The JAK-STAT Pathway: A Therapeutic Target in Hematological Malignancies

Current Cancer Drug Targets, Vol. 6, Iss. 8, 2006-01 ,pp. : 671-679

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting of Jak/STAT Pathway in Antigen Presenting Cells in Cancer

Current Cancer Drug Targets, Vol. 7, Iss. 1, 2007-02 ,pp. : 71-77

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting the IL-6 Pathway in Multiple Myeloma and its Implications in Cancer-Associated Gene Hypermethylation

Medicinal Chemistry, Vol. 7, Iss. 5, 2011-09 ,pp. : 473-479

Bentham Science Publishers

Access to resources Recommend Favorite

Genes and Proteins Governing the Cellular Sensitivity to HSP90 Inhibitors: A Mechanistic Perspective

Current Cancer Drug Targets, Vol. 3, Iss. 5, 2003-10 ,pp. : 331-341

Bentham Science Publishers

Access to resources Recommend Favorite